Home › Search
Search
439 results for "lecanemab".
Research summaries 393
Showing the best 200 of 393, 151–160, page 16 of 20. Filter these by subject, year and score in the research library →
-
Multiple ischemic strokes in a patient treated with Lecanemab: a case reportResearch summary
Research summaries · alzhub.org/study/multiple-ischemic-strokes-in-a-patient-treated-with-lecanemab-a-case-41102913
… amyloid-lowering drug Lecanemab who developed both ARIA-H and ARIA-E, as well as multiple asymptomatic ischemic infarctions. Extensive workup did not reveal another clear cause for infarction. These infarcts, in conjunction with …
-
Progressive Amyloid-Related Imaging Abnormalities After Discontinuation of Lecanemab in Early Alzheimer Disease in an APOE ε2/ε4 CarrierResearch summary
Research summaries · alzhub.org/study/progressive-amyloid-related-imaging-abnormalities-after-42862019
… after discontinuation of lecanemab in a patient with early-onset Alzheimer's disease carrying the rare APOE ε2/ε4 genotype. Results After two infusions, mild ARIA-edema (ARIA-E) and ARIA-hemorrhage (ARIA-H) were detected on …
-
Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysisResearch summary
Research summaries · alzhub.org/study/real-world-application-of-lecanemab-in-early-stage-alzheimer-s-41250246
… Following 12 months of lecanemab therapy, amyloid PET exhibited a significant reduction in brain amyloid burden. These data support that lecanemab appears to be generally tolerated in Asian population. The IRSE and ARIA-E events …
-
Research summaries · alzhub.org/study/reducing-aria-risk-in-alzheimer-s-disease-real-world-impact-of-lt-i-40801838
… aducanumab and 19 patients on lecanemab on a genotype-informed protocol in a private practice setting. ARIA-E and ARIA-H each occurred in 4% of the aducanumab group and 5% of the lecanemab group. Plaque clearance was achieved in …
-
Amyloid Clearance and Transient CSF Aβ40 Reduction in a Case of ARIA-E/H Following Lecanemab TreatmentResearch summary
Research summaries · alzhub.org/study/amyloid-clearance-and-transient-csf-a40-reduction-in-a-case-of-aria-e-40835473
… (ARIA)-E/H following lecanemab treatment in a 70-year-old man with mild cognitive impairment due to Alzheimer's disease. Generalized seizures occurred after the third infusion and were accompanied by fluid attenuated inversion …
-
Research summaries · alzhub.org/study/population-pharmacokinetic-pharmacodynamic-analyses-of-amyloid-36165093
Lecanemab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to soluble Aβ aggregate species, while demonstrating low affinity for Aβ monomer. This article describes the population pharmacokinetic (PK) …
-
Six-month follow-up of ARIA-H and iron deposition in real-world lecanemab therapy for Alzheimer's disease: Evidence from a Chinese 7T MRI cohortResearch summary
Research summaries · alzhub.org/study/six-month-follow-up-of-aria-h-and-iron-deposition-in-real-world-41476028
Introduction With the approval of lecanemab for treating Alzheimer's disease (AD), there is an urgent need to evaluate its safety and treatment effects on biomarkers in real-world practice. Methods Patients receiving lecanemab (n …
-
Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world studyResearch summary
Research summaries · alzhub.org/study/amyloid-related-imaging-abnormalities-in-japanese-patients-with-41936348
… Japanese AD cohort, Lecanemab demonstrated a manageable safety profile in a real-world setting. In exploratory analyses, potential trends toward a higher frequency of ARIA were observed in patients with lower MMSE scores, higher …
-
Research summaries · alzhub.org/study/lecanemab-autorizado-para-tratamiento-del-alzheimer-en-pacientes-que-d2104574
… marketing authorization for lecanemab only in Alzheimer's patients who have one or no copies of the ApoE4 gene. This population is less likely to experience ARIA, a serious adverse reaction involving brain swelling and possible …
-
Research summaries · alzhub.org/study/fatal-iatrogenic-cerebral-amyloid-related-encephalitis-in-a-patient-2f35ceff
… monoclonal antibody lecanemab where she was treated with the placebo, and subsequently in the open label extension study where she received lecanemab infusions every two weeks. After the third infusion, she suffered a seizure …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.